Related references
Note: Only part of the references are listed.The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?
Laura C. Coates et al.
ARTHRITIS CARE & RESEARCH (2021)
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
Xenofon Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study
Christine Ballegaard et al.
RHEUMATOLOGY (2021)
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
Philip J Mease et al.
Lancet Rheumatology (2021)
Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?
Joy Feld et al.
RHEUMATOLOGY (2020)
Patient's experience of psoriatic arthritis: a conceptual model based on qualitative interviews
Alexis Ogdie et al.
RMD OPEN (2020)
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
Philip S. Helliwell et al.
RMD OPEN (2020)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life
Sibel Zehra Aydin et al.
CLINICAL RHEUMATOLOGY (2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype
Pedro Machado et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis
Juergen Braun et al.
RHEUMATOLOGY (2010)
Validity of the Bath Ankylosing Spondylitis Disease Activity Index for the Evaluation of Disease Activity in Axial Psoriatic Arthritis
Jose Luis Fernandez-Sueiro et al.
ARTHRITIS CARE & RESEARCH (2010)
Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations
I. H. Song et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis?
WJ Taylor et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2004)
Share Paper
